PriceTargets.com logo

BioCardia - BCDA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $25.00
  • Forecasted Upside: 1,600.68%
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 1 Strong Buy Ratings
$1.47 As of 12/4/2025 05:00 PM ET
▲ +0.05 (3.52%)

This chart shows the closing price for BCDA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioCardia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCDA

Analyst Price Target is $25.00
▲ +1,600.68% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for BioCardia in the last 3 months. The average price target is $25.00, with a high forecast of $25.00 and a low forecast of $25.00. The average price target represents a 1,600.68% upside from the last price of $1.47.

This chart shows the closing price for BCDA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 contributing investment analysts is to moderate buy stock in BioCardia. This rating has held steady since September 2025, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/23/2025Zacks ResearchUpgradeHold
9/22/2025HC WainwrightReiterated RatingBuy ➝ Buy$25.00
1/30/2025Alliance Global PartnersUpgradeHold ➝ Strong-Buy
12/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
11/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
10/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
8/16/2024HC WainwrightBoost TargetBuy ➝ Buy$4.00 ➝ $25.00
7/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
5/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
11/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$60.00
10/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$60.00
9/6/2023HC WainwrightLower TargetBuy ➝ Buy$135.00 ➝ $60.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$135.00
7/28/2023Alliance Global PartnersDowngradeBuy ➝ Neutral
7/24/2023HC WainwrightReiterated RatingBuy ➝ Buy$135.00
3/30/2023HC WainwrightReiterated RatingBuy$135.00
11/17/2022Alliance Global PartnersLower Target$172.50 ➝ $90.00
11/11/2022Dawson JamesDowngradeBuy ➝ Neutral
5/26/2022Maxim GroupLower Target$60.00
2/3/2022Brookline Capital ManagementReiterated RatingBuy
12/20/2021HC WainwrightInitiated CoverageBuy$135.00
4/22/2021Dawson JamesReiterated RatingBuy ➝ Neutral
4/16/2021Dawson JamesDowngradeBuy ➝ Neutral
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 3 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 3 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

BioCardia logo
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
Read More

Today's Range

Now: $1.47
Low: $1.40
High: $1.49

50 Day Range

MA: $1.37
Low: $1.22
High: $1.56

52 Week Range

Now: $1.47
Low: $1.00
High: $3.20

Volume

108,130 shs

Average Volume

60,355 shs

Market Capitalization

$15.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67

Frequently Asked Questions

What sell-side analysts currently cover shares of BioCardia?

The following equities research analysts have issued stock ratings on BioCardia in the last year: Alliance Global Partners, HC Wainwright, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for BCDA.

What is the current price target for BioCardia?

0 Wall Street analysts have set twelve-month price targets for BioCardia in the last year. Their average twelve-month price target is $25.00, suggesting a possible upside of 1,600.7%. HC Wainwright has the highest price target set, predicting BCDA will reach $25.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $25.00 for BioCardia in the next year.
View the latest price targets for BCDA.

What is the current consensus analyst rating for BioCardia?

BioCardia currently has 1 sell rating, 1 hold rating, 1 buy rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BCDA.

What other companies compete with BioCardia?

Other companies that are similar to BioCardia include Celularity, Aligos Therapeutics, TScan Therapeutics, Eliem Therapeutics and Tenax Therapeutics. Learn More about companies similar to BioCardia.

How do I contact BioCardia's investor relations team?

BioCardia's physical mailing address is 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA, 94070. The company's listed phone number is (650) 226-0120 and its investor relations email address is [email protected]. The official website for BioCardia is www.biocardia.com. Learn More about contacing BioCardia investor relations.